Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks higher amid US holiday-thinned trade

Tue, 04th Jul 2023 12:08

(Alliance News) - Stock prices in London were higher at midday on Tuesday, with the absence of US markets and any major economic releases keeping trade muted.

"With US markets closed for the 4th July holiday, it is expected to be a quieter-than-normal day of trading with the potential for wider swings on lower volumes," said Victoria Scholar, head of investment at interactive investor.

The FTSE 100 index was up 10.31 points, or 0.1%, at 7,537.57. The FTSE 250 was up 44.46 points, or 0.2%, at 18,552.23, and the AIM All-Share was up 0.95 of a point, or 0.1%, at 755.28.

The Cboe UK 100 was up 0.1% at 751.83, the Cboe UK 250 was up 0.3% at 16,240.33, and the Cboe Small Companies was up 0.2% at 16,240.33.

Though Tuesday's economic calendar is quiet, the rest of the week will be busier, particularly in the US.

The US Federal Open Market Committee will publish its latest meeting minutes on Wednesday and a series of US jobs data will be released on Thursday and Friday.

"While the potential for further hawkish pricing for the Fed seems limited, there is a good chance of a dovish readjustment in the case of soft jobs data," said Ipek Ozkardeskaya, senior analyst at Swissquote Bank.

According to the CME FedWatch Tool, markets currently see an 87% chance the US central bank will hike interest rates by 25 basis points at its next meeting.

The dollar was slightly weaker on Tuesday afternoon, though Francesco Pesole at ING noted that volatility for the US currency will likely pick up from Wednesday with the release of the FOMC minutes.

The pound was quoted at USD1.2710 at midday on Tuesday in London, up from USD1.2675 at the close on Monday. The euro stood at USD1.0903, virtually unchanged against USD1.0905 on Monday. Against the yen, the dollar was trading at JPY144.39, lower compared to JPY144.59.

In London, AstraZeneca was the top blue-chip performer at midday on Tuesday, up 2.5%.

The stock had closed 4.9% lower on Monday as test results suggested its new lung cancer drug may be less successful than hoped, despite being generally positive.

Meanwhile, Sainsbury's was among the worst performers in the FTSE 100, down 1.4%, despite reporting an improved first quarter, with grocery sales on the up.

The grocer said in the 16 weeks to June 24, total retail sales excluding fuel grew 9.2% annually. Like-for-like sales climbed 9.8% on-year, also excluding fuel. Fuel sales alone fell 21%.

Sainsbury's said first-quarter growth was led by convenience stores and supermarkets, with customers continuing to return to stores.

Zoe Gillespie, investment manager at RBC Brewin Dolphin, said the results were "resilient".

"In an environment that many feared would lead to customers trading down, the supermarket continues to grow sales and its guidance for the year is largely unchanged...With a relatively strong balance sheet, excess cash flow, and growing market share, Sainsbury's looks well placed among its peers," she said.

In the FTSE 250, Wizz Air added 1.8%.

The Budapest-based budget airline carried 5.3 million passengers in June, up 23% from 4.3 million a year before and 6.0% from 5.0 million in May.

Wizz Air's planes were 92.2% full last month, up from 86.1% in June 2022 and 90.2% in May.

Russ Mould, investment director at AJ Bell commented low-cost airlines were having "a whale of a time" thanks to the sharp rebound in travel demand.

"The decision to expand fleet capacity during the cost-of-living crisis was a calculated risk and the move is now paying off," he said.

Elsewhere in London, Foresight Group added 0.9% following a largely strong set of annual results.

The infrastructure and private equity investment manager said revenue in the year ended March 31 increased by 38% to GBP119.2 million from GBP86.1 million the prior year.

Assets under management at March 31 climbed by 38% to GBP12.2 billion from GBP8.8 billion the year before, while funds under management were up by 35% to GBP9.0 billion from GBP6.7 billion year-on-year.

On AIM, Alba Minerals surged 53% after the Europe-focused mineral explorer announced it had been granted the ecological permits it requires for its planned dewatering and the exploration of the Clogau-St David's Gold Mine in North Wales.

The company has sought ecological permits to enable it to start the dewatering process since 2021.

Alba Mineral's technical team and contracts are now undertaking the necessary on-site preparations so that the dewatering exercise can start as soon as possible.

In European equities on Tuesday, the CAC 40 in Paris was down 0.1%, while the DAX 40 in Frankfurt was down 0.3%.

Brent oil was quoted at USD75.61 a barrel at midday in London on Tuesday, down a touch from USD75.92 late Monday. Gold was quoted at USD1,928.81 an ounce, slightly higher against USD1,927.00.

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
27 Jun 2024 13:00

German vaccine panel endorses Astra-Sanofi's RSV shot for infants

FRANKFURT, June 27 (Reuters) - Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.

Read more
26 Jun 2024 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar approval in Japan.

Read more
25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

Read more
25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

Read more
25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.

Read more
24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
24 Jun 2024 14:56

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.